Clinical Trial Search

Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001

Primary: PFS — 29.8 Months

Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001

Primary: Response Rate — 1; 2; 4 participants

Primary: Percentage of Patients That Achieve Maximal Surgical Debulking — 10 Participants

Primary: Best Overall Tumor Response — 6; 25; 10; 5 participants

Primary: Progression-free Survival — 8.85; 8.32 months

Primary: Number of Protocol Defined Adverse Events in Patients Receiving Neoadjuvant Carboplatin, Paclitaxel, and Bevacizumab — 7 protocol defined adverse events

Primary: Progression Free Survival in Patients With Platinum and Taxane Refractory Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer With Bendamustine…

Primary: Overall Response Rate (ORR) — 0; 0 participants

Primary: Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) Population…

Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants

Primary: Overall Survival — 32 months

Primary: Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2) — 500 mg/m2

Primary: Overview of Treatment-emergent Adverse Events (TEAEs) — 3; 13; 11; 2 Participants

Primary: Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher — 20 Participants

Primary: Tolerated Dose — 80 mg/m^2

Primary: Number of Patients With Dose-limiting Toxicities (DLTs) — 0; 0 Participants

Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants

Primary: Number of Participants Assessed for Safety and Tolerability as Assessed by NCI CTCAE v3.0 — 3; 3; 4; 2 Participants

Primary: Progression Free Survival (PFS) — 20.0; 22.2 Months — p=0.199

Primary: Combined Best Overall Response Rate Based on Investigator Assessment — 0; 12 percentage of participants

Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants

Primary: Clinical Response Rate. — 0; 19; 21; 60 percentage of participants

Primary: Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1 — 30.6; 43.1 percentage of participants

Primary: Objective Response Rate (ORR) Investigator Assessment: % of Patients in the Group Who Achieve a Complete Response(CR) or Partial Response(PR) According to RECIST…

Primary: Tumor Response Type: CR, PR, SD or PD — 1; 4; 9; 6 Participants

Primary: Number of Patients With Treatment-emergent Adverse Events — 12; 6; 6; 12 Participants

Primary: Progression-free Survival — 25 months

Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants